ARTEC, Inc. has made key appointments with the goal of initiating the production and global distribution of Tubercin and related immunostimulant medicines. “R&D of Tubercin is complete, requiring no further refinement or alteration in terms of its formulation. Our new business associates are joining ARTEC, Inc. in order to stimulate and enforce the production of this potentially promising immunostimulant to combat HIV and Cancer,” said Dr. Ronald Shinn, president and chairma...